Fertility and pregnancy during cancer treatment: what to discuss before and during care
Some cancer treatments can affect fertility temporarily or permanently, but risk differs by person and treatment. If future biological parenthood matters to you — or you are unsure — fertility is best discussed early and, when medically feasible, before treatment begins.
Short answer
Ask about fertility before treatment when possible because some preservation options are most useful before exposure to potentially gonadotoxic therapy. Reduced fertility does not mean pregnancy is impossible, and fertility potential is a different question from pregnancy safety. There is no universal contraception or conception timeline for every cancer treatment.
Why does fertility risk vary?
Risk depends on the treatment type and dose or intensity, the site of radiation or surgery, age, fertility before treatment and other clinical factors. Different chemotherapy drugs, radiation fields, operations, hormonal therapies, targeted therapies and immunotherapies can affect reproduction in different ways. Age or cancer type alone cannot provide a reliable personal infertility percentage.
Why discuss fertility before treatment when feasible?
ASCO recommends discussing infertility risk as early as possible and referring people who are interested in fertility preservation — or uncertain about it — to reproductive specialists. Some options are most useful before exposure to potentially gonadotoxic treatment. If cancer therapy is urgent, fertility preservation should not automatically delay it; oncology and reproductive teams must coordinate what is safe and feasible.
Which preservation options are established?
For postpubertal males, sperm cryopreservation is established, and sperm retrieval may be considered when a sample cannot be provided. For appropriate female patients, established options include mature-oocyte and embryo cryopreservation, with ovarian-tissue cryopreservation available in selected circumstances. Ovarian transposition or fertility-sparing surgery may be relevant in carefully selected cancer or radiation settings.
What remains emerging or experimental?
Not every technique should be presented as equivalent to established preservation. In-vitro maturation is an emerging option in selected settings. Prepubertal testicular-tissue cryopreservation remains experimental and belongs in specialized research protocols. GnRH agonists do not replace established fertility-preservation methods, although they may be used as an adjunct in selected clinical situations.
Fertility and pregnancy safety are different questions
Pregnancy can still be possible when fertility is reduced, but that does not mean a particular cancer treatment is safe during pregnancy. Fertility testing also cannot determine whether a drug, radiation plan or operation is safe for a pregnancy. If pregnancy exists or is possible now, tell the oncology team promptly so care can be coordinated with obstetric or maternal-fetal medicine specialists when appropriate.
Contraception during and after treatment
Cancer teams may recommend contraception during a treatment and for a treatment-specific period afterward, but the method and duration vary with the exact medicine, radiation plan and clinical situation. Some product labels contain specific reproductive warnings. Reffaq therefore does not give a generic number of weeks or months after the last dose.
Can fertility tests give a definitive answer?
Tests such as AMH, ovarian-reserve assessment or semen analysis can be useful in a defined clinical context, but no single result reliably predicts future fertility or the chance of pregnancy for an individual. Results must be interpreted with age, reproductive history, the treatment plan and timing, and other clinical information.
Questions to ask before treatment starts
Ask whether the proposed treatment may affect fertility, which parts of the plan drive the risk, whether there is medically safe time for a reproductive-specialist consultation, which preservation options fit your circumstances and their limits, what contraception guidance applies to your treatment, what to do if pregnancy is possible now, and who should reassess fertility after treatment.
What does the evidence say together?
NCI resources and ASCO guidance agree that fertility risk varies by treatment and patient, and that early counseling and reproductive-specialist referral matter when future fertility is a concern or the patient is uncertain. Pregnancy guidance also makes clear that an established pregnancy requires multidisciplinary oncology and obstetric care rather than a generic list of “safe” cancer treatments.
How should you use this information?
If treatment has not started and future biological parenthood matters to you — or you are unsure — ask the oncology team to discuss fertility risk and whether prompt referral to a reproductive specialist is appropriate. If treatment has already started, do not assume all options are lost and do not stop therapy; ask what can be assessed now or later. If pregnancy exists or is possible, tell the team promptly.
What did the studies find?
Core medical sources
This page is for general education. It does not estimate your fertility, diagnose infertility, select a preservation method or contraception, or determine when pregnancy is safe. Do not delay, stop or change cancer treatment based on this page.
Editorial and evidence review
The Reffaq Cancer Magazine Editorial Team prepared this page and reviewed its evidence by comparing claims with trusted medical and scientific sources, using AI to assist research and comparison under Reffaq editorial oversight. This is editorial evidence review, not review by a licensed physician. If documented human medical review occurs, we clearly identify the reviewer, credentials and scope.
Who we are and how Reffaq Cancer Magazine content is prepared